Filing Flows › Comparisons › LGVN vs DNTH
Longeveron vs Dianthus Therapeutics: LGVN and DNTH compared
Longeveron is the larger company: $287K of revenue in its latest quarter (Q2 2026) against $284K for Dianthus Therapeutics (Q4 2025). Longeveron is growing faster (-9% against -79% a year earlier).
Where the money goes: LGVN and DNTH
Longeveron (LGVN) · Q2 2026
Longeveron, Q2 2026: revenue $287K (-9% year over year), net loss $6.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Dianthus Therapeutics (DNTH) · Q4 2025
Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.
| Longeveron (LGVN) | Dianthus Therapeutics (DNTH) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $287K | $284K |
| Revenue growth, Y/Y | -9% | -79% |
| Operating margin | n/m | n/m |
| Net earnings | −$6.1M | −$64.4M |
| Operating cash flow | −$5.7M | −$47.0M |
Questions
Which is bigger, Longeveron or Dianthus Therapeutics?
Longeveron is the larger company: $287K of revenue in its latest quarter (Q2 2026) against $284K for Dianthus Therapeutics (Q4 2025).
Is Longeveron or Dianthus Therapeutics growing faster?
Longeveron is growing faster (-9% against -79% a year earlier).
More: Longeveron earnings · how Longeveron makes money · Dianthus Therapeutics earnings · how Dianthus Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-K filed Mar 9, 2026). Fiscal quarters can end on different dates. Not investment advice.